Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: August 10, 2022

Details for Patent: 6,762,180

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 6,762,180 protect, and when does it expire?

Patent 6,762,180 protects OFEV and is included in one NDA.

This patent has sixty patent family members in forty-two countries.

Summary for Patent: 6,762,180
Title: Substituted indolines which inhibit receptor tyrosine kinases
Abstract:Indolinones of the formula ##STR1## having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycar bonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoy l-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxyca rbonyl-2-indolinone.
Inventor(s): Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Van Meel; Jacobus (Moedling, AT), Redemann; Norbert (Biberach, DE), Tontsch-Grunt; Ulrike (Baden, AT), Spevak; Walter (Oberrohrbach, AT), Hilberg; Frank (Vienna, AT)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:09/678,682
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,762,180

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,762,180

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 49 208Oct 13, 1999
Germany100 42 696Aug 31, 2000

International Family Members for US Patent 6,762,180

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 026036 See Plans and Pricing
Austria 439342 See Plans and Pricing
Australia 1023301 See Plans and Pricing
Australia 781939 See Plans and Pricing
Bulgaria 106587 See Plans and Pricing
Bulgaria 65983 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.